NLS Pharmaceutics Announces Company Update Webcast

Rhea-AI Summary

NLS Pharmaceutics announces plans to showcase its global strategic R&D progress and platform in an upcoming webcast event on June 30, 2023. The event will include discussions on the initiation of Phase 3 program AMAZE for Mazindol ER, pipeline goals for 2023/2024, key financials, funding strategy update, and corporate development.

Positive

• NLS will provide updates on the initiation of Phase 3 program AMAZE for Mazindol ER, which could positively impact the stock price. The company will also discuss its pipeline goals for 2023/2024, which may generate investor interest. Additionally, NLS will provide key financial updates, which could reassure investors about the company's financial health.

Negative

• No negative takes found.

• Members of Executive Leadership Team to Discuss initiation of Phase 3, Pipeline updates, Key Financials, Corporate Development, and the other topics
• NLS to Webcast its Event Friday, June 30 at 11:00am ET

ZURICH, SWITZERLAND / ACCESSWIRE / June 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced plans to showcase its global strategic R&D progress and platform, including:

• Feedback from the SLEEP 2023 APSS Conference
• Initiation of the Phase 3 program AMAZE for Mazindol ER
• Pipeline Goals for 2023/2024
• Key Financials
• Funding Strategy Update
• Corporate Development

Webcast Information

The event will be held June 30, 2023, at 11:00 am ET and will include a video stream on the Investors section of the Company's website here or at the SummitCast event page here. A replay will be available on the NLS' website within 48 hours after the event.

About NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.

For additional information:

Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
www.nlspharma.com

SOURCE: NLS Pharmaceutics AG

View source version on accesswire.com:
https://www.accesswire.com/762022/NLS-Pharmaceutics-Announces-Company-Update-Webcast

FAQ

What will be discussed in the webcast event?

The webcast event will include discussions on the initiation of Phase 3 program AMAZE for Mazindol ER, pipeline goals for 2023/2024, key financials, funding strategy update, and corporate development.

How could the initiation of Phase 3 program AMAZE impact the stock price?

The initiation of Phase 3 program AMAZE for Mazindol ER could positively impact the stock price.

What updates will be provided about the pipeline goals?

NLS will provide updates on its pipeline goals for 2023/2024.

Will there be any updates on the company's financials?

Yes, key financial updates will be provided during the webcast event.

When and where will the webcast event take place?

The webcast event will take place on June 30, 2023, at 11:00 am ET. It can be accessed through the Investors section of the company's website or the SummitCast event page.

Will there be a replay of the webcast event?

Yes, a replay of the webcast will be available on NLS' website within 48 hours after the event.